Dr. Richard Furman on Evaluating the Role of Idelalisib in Treating CLL

In this panel discussion from OncLive, Dr. Richard Furman evaluates the role of idelalisib in the treatment of patients with CLL.

Author: lymphomaprogram

Located on the Upper East Side of New York City, the Lymphoma Program at Weill Cornell Medical College/NewYork Presbyterian Hospital is internationally recognized for our efforts to enable patients with non-Hodgkin lymphoma, Hodgkin disease and related disorders to have the best possible clinical outcome, including cure when possible.

Post a Comment